{
    "ticker": "CRVS",
    "name": "Corvus Pharmaceuticals, Inc.",
    "description": "Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cancer treatment. Founded in 2014 and headquartered in Burlingame, California, Corvus is at the forefront of immuno-oncology, leveraging the power of the immune system to fight cancer. The company's lead product candidate, ciforadenant, is a potent and selective A3 adenosine receptor antagonist that is being evaluated in clinical trials for the treatment of various solid tumors. Corvus is also developing other product candidates, including monoclonal antibodies and combination therapies aimed at enhancing the efficacy of existing cancer treatments. The company aims to provide new treatment options for patients with unmet medical needs, particularly in the areas of lung cancer and hematologic malignancies. With a strong pipeline of drug candidates and a commitment to scientific excellence, Corvus Pharmaceuticals is dedicated to advancing the field of immunotherapy and improving the lives of cancer patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Burlingame, California, USA",
    "founded": "2014",
    "website": "https://www.corvuspharma.com",
    "ceo": "Richard A. Miller",
    "social_media": {
        "twitter": "https://twitter.com/CorvusPharma",
        "linkedin": "https://www.linkedin.com/company/corvus-pharmaceuticals/"
    },
    "investor_relations": "https://investors.corvuspharma.com",
    "key_executives": [
        {
            "name": "Richard A. Miller",
            "position": "CEO"
        },
        {
            "name": "Michael P. B. R. Heller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "Ciforadenant",
                "Corvus-100"
            ]
        }
    ],
    "seo": {
        "meta_title": "Corvus Pharmaceuticals, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Corvus Pharmaceuticals, Inc., a leader in immuno-oncology focused on developing innovative therapies for cancer treatment.",
        "keywords": [
            "Corvus Pharmaceuticals",
            "Cancer Treatment",
            "Immunotherapy",
            "Adenosine Receptor Antagonist",
            "Ciforadenant"
        ]
    },
    "faq": [
        {
            "question": "What does Corvus Pharmaceuticals specialize in?",
            "answer": "Corvus Pharmaceuticals specializes in developing innovative therapies for cancer treatment, particularly in immuno-oncology."
        },
        {
            "question": "Where is Corvus Pharmaceuticals headquartered?",
            "answer": "Corvus Pharmaceuticals is headquartered in Burlingame, California, USA."
        },
        {
            "question": "What is Corvus's lead product candidate?",
            "answer": "Corvus's lead product candidate is ciforadenant, an A3 adenosine receptor antagonist."
        },
        {
            "question": "When was Corvus Pharmaceuticals founded?",
            "answer": "Corvus Pharmaceuticals was founded in 2014."
        }
    ],
    "competitors": [
        "NVTA",
        "CLVS",
        "EXEL",
        "IMMU"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "MRNA"
    ]
}